Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Bronchodilators Market by Drug class (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor and Combination Drugs), by Indication (Asthma, COPD, and Others), and Route of Administration (Oral, Injection, and Inhaler): Global Opportunity Analysis and Industry Forecast, 2019–2026

A03597
Pages: 207
Feb 2020 | 2220 Views
 
Author(s) : Snehal Manjrekar , Onkar Sumant
Tables: 102
Charts: 41
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Bronchodilators Market

Request Now !

The global bronchodilators market size was valued at $27,580.00 million in 2018 and is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Bronchodilators are the drugs that relax muscles that tighten around the airways. Bronchodilators open the airway and lets more air move in and out of the lungs. Bronchodilators are also used to reduce mucus from the lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhalation bronchodilators also have effects on mucociliary clearance. Bronchodilators are used in the treatment of obstructive lung diseases by relaxing the lungs muscles and widening the airways (bronchi). They are used in the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), across the globe is the major factor driving the bronchodilators market growth. In addition, rise in disposable income, geriatric population, and increase in awareness of healthcare among population are anticipated to boost the market growth. Further, increased usage of bronchodilators for the treatment of cystic fibrosis fuels the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators are anticipated to hamper the market growth. On the contrary, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the bronchodilators market.

Bronchodilators Market

Get more information on this report : Request Sample Pages

Global Bronchodilators Market Segmentation

The bronchodilators market is segmented on the basis of indication, drugs type, route of administration, and region. Based on indication the market is categorized into asthma, chronic obstructive pulmonary disease (COPD) and others. By drugs type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitor, and combination drugs. On the basis of route of administration, the market is categorized into oral, injection and inhaler. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Bronchodilators Market
By Indication

Your browser does not support the canvas element.

Others segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Indication Segment Review

By indication, the asthma segment accounted for the majority of market share in 2018 and is expected to exhibit a prominent growth rate in the near future. This is attributed to the significant surge in the prevalence of asthma across the globe. For instance, according to Asthma and Allergy Foundation of America, asthma accounts for 9.8 million hospital visits, 188,968 discharges from hospital inpatient care and 1.8 million emergency department visits each year. The COPD segment is expected to show lucrative growth owing to significant surge in adoption of smoking along with exposure to certain gases or fumes in workplaces, exposure to heavy amounts of secondhand smoke, pollution, and frequent use of cooking fire without proper ventilation are responsible for COPD.

Bronchodilators Market
By Drug Type

Your browser does not support the canvas element.

Anticholinergics segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Drug Type Segment Review

By drug type, the anticholinergics segment dominated the bronchodilators market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that anticholinergics are available in both long acting and short acting forms. In addition, anticholinergic bronchodilators block the parasympathetic nerve reflexes that constrict the airways and enable the air passages to remain open. Anticholinergic bronchodilators are widely being used to treat chronic obstructive pulmonary disease. The combination drug segment is anticipated to grow at the fastest CAGR in the forecast period. This growth is attributed to their properties of dilating air passages and making air flow easier. Combination drugs are most commonly a bronchodilator and a steroid.

Bronchodilators Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

North America segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region Segment Review

North America held the largest share in the bronchodilators market in 2018, followed by Europe. In addition, significant increase in cystic fibrosis and increase in government initiates towards increasing awareness regrading COPD, asthma and other chronic respiratory disorders. Furthermore, presence of leading players of the bronchodilators market such as AstraZeneca, Teva Pharmaceutical Industries Ltd., among others contributes to the market growth. 

However, Asia-Pacific is anticipated to grow at the highest rate during the analysis period. This is attributed to increase in respiratory disorder patient pool in Asia-Pacific, and significant improvement in the healthcare sector in this region. Moreover, improving healthcare infrastructure, increase in availability of these drugs in the market and rise in smoking habits in this region is anticipated to contribute to the market growth. In Europe, key players are adopting partnership as their key developmental strategy to introduce new bronchodilators and such partnerships are expected to give an edge to these companies over others. Moreover, factors that promote the growth of the bronchodilators market in Europe include rise in demand for bronchodilators in the pharmaceutical sector and increase in investment by the European Union for R&D in the healthcare sector. 

Comprehensive competitive analysis and profiles of major market players such as, Boehringer Ingelheim, GlaxoSmithKline, F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc and Abbott Laboratories are provided in this report.

Key Benefits for Stakeholders:

  • The bronchodilators market share and analysis is based on a comprehensive analysis of key developments in the bronchodilators industry.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global bronchodilators market.
  • The study provides an in-depth analysis of the market trends to elucidate the imminent investment pockets.
  • The global bronchodilators market trends are studied from 2018 to 2026.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative global bronchodilators market analysis from 2019 to 2026 is provided to determine the market potential.

Key Market Segments:

By Indication

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Others

By Drug Type

  • Sympathomimetics
  • Anticholinergics
  • Phosphodiesterase Inhibitor
  • Combination Drugs

By Route of Administration

  • Oral
  • Injection
  • Inhaler

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry

3.4. Top player positioning
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in incidence of asthma and COPD
3.5.1.2. Surge in government initiatives

3.5.2. Restraint

3.5.2.1. Side effects associated with bronchodilators

3.5.3. Opportunity

3.5.3.1. Various growth opportunities in emerging economies

CHAPTER 4: BRONCHODILATORS MARKET, BY INDICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Asthma

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country

4.3. Chronic obstructive pulmonary disease (COPD)

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country

4.4. Others

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country

CHAPTER 5: BRONCHODILATORS MARKET, BY DRUG TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Sympathomimetics

5.2.1. Market size and forecast
5.2.2. Market share analysis, by country

5.3. Anticholinergics

5.3.1. Market size and forecast
5.3.2. Market share analysis, by country

5.4. Phosphodiesterase Inhibitors

5.4.1. Market size and forecast
5.4.2. Market share analysis, by country

5.5. Combination Drugs

5.5.1. Market size and forecast
5.5.2. Market share analysis, by country

CHAPTER 6: BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Oral

6.2.1. Market size and forecast
6.2.2. Market share analysis, by country

6.3. Injection

6.3.1. Market size and forecast
6.3.2. Market share analysis, by country

6.4. Inhalers

6.4.1. Market size and forecast
6.4.2. Market share analysis, by country

CHAPTER 7: BRONCHODILATORS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug type
7.2.5. Market size and forecast, by route of administration

7.2.5.1. U.S. market size and forecast, by indication
7.2.5.2. U.S. market size and forecast, by drug type
7.2.5.3. U.S. market size and forecast, by route of administration
7.2.5.4. Canada market size and forecast, by indication
7.2.5.5. Canada market size and forecast, by drug type
7.2.5.6. Canada market size and forecast, by route of administration
7.2.5.7. Mexico market size and forecast, by indication
7.2.5.8. Mexico market size and forecast, by drug type
7.2.5.9. Mexico market size and forecast, by route of administration

7.3. Europe

7.3.1. Key growth factors and opportunities
7.3.2. Europe Market size and forecast, by country
7.3.3. Europe Market size and forecast, by indication
7.3.4. Europe Market size and forecast, by drug type
7.3.5. Europe Market size and forecast, by route of administration

7.3.5.1. Germany market size and forecast, by indication
7.3.5.2. Germany market size and forecast, by drug type
7.3.5.3. Germany market size and forecast, by route of administration
7.3.5.4. France market size and forecast, by indication
7.3.5.5. France market size and forecast, by drug type
7.3.5.6. France market size and forecast, by route of administration
7.3.5.7. UK market size and forecast, by indication
7.3.5.8. UK market size and forecast, by drug type
7.3.5.9. UK market size and forecast, by route of administration
7.3.5.10. Rest of Europe market size and forecast, by indication
7.3.5.11. Rest of Europe market size and forecast, by drug type
7.3.5.12. Rest of Europe market size and forecast, by route of administration

7.4. Asia-Pacific

7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by drug type
7.4.5. Asia-Pacific market size and forecast, by route of administration

7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug type
7.4.6.3. Japan market size and forecast, by route of administration
7.4.6.4. China market size and forecast, by indication
7.4.6.5. China market size and forecast, by drug type
7.4.6.6. China market size and forecast, by route of administration
7.4.6.7. India market size and forecast, by indication
7.4.6.8. India market size and forecast, by drug type
7.4.6.9. India market size and forecast, by route of administration
7.4.6.11. Rest of Asia-Pacific market size and forecast by indication
7.4.6.12. Rest of Asia-Pacific market size and forecast, by drug type
7.4.6.13. Rest of Asia-Pacific market size and forecast, by route of administration

7.5. LAMEA

7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by drug type
7.5.5. LAMEA market size and forecast, by route of administration
7.5.5.1. Brazil market size and forecast, by indication
7.5.5.2. Brazil market size and forecast, by drug type
7.5.5.3. Brazil market size and forecast, by route of administration
7.5.5.4. Saudi Arabia market size and forecast, by indication
7.5.5.5. Saudi Arabia market size and forecast, by drug type
7.5.5.6. Saudi Arabia market size and forecast, by route of administration
7.5.5.7. South Africa market size and forecast, by indication
7.5.5.8. South Africa market size and forecast, by drug type
7.5.5.9. South Africa market size and forecast, by route of administration
7.5.5.10. Rest of LAMEA market size and forecast, by indication
7.5.5.11. Rest of LAMEA market size and forecast, by drug type
7.5.5.12. Rest of LAMEA market size and forecast, by route of administration

CHAPTER 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. AstraZeneca plc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Boehringer Ingelheim International GmbH

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. GlaxoSmithKline Plc.

8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. F. Hoffmann-La Roche Ltd.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance

8.6. Novartis AG.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Pfizer Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. SANOFI

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. Teva Pharmaceutical Industries Ltd.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. Vectura Group Plc.

8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance

LIST OF TABLES

TABLE 01. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 02. BRONCHODILATORS MARKET FOR ASTHMA MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 04. BRONCHODILATORS MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 06. SYMPATHOMIMETICS BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. BRONCHODILATORS FOR ANTICHOLINERGICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. BRONCHODILATORS MARKET FOR PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 09. BRONCHODILATORS MARKET FOR COMBINATION DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 10. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 11. BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 12. BRONCHODILATORS MARKET FOR INJECTION, BY REGION, 2018–2026 ($MILLION)
TABLE 13. BRONCHODILATORS MARKET FOR INHALE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. BRONCHODILATORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15. NORTH AMERICA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 18. NORTH AMERICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 19. U.S. BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 20. U.S. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 21. U.S. BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 22. CANADA BRONCHODILATORS MARKET BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. CANADA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 24. CANADA BRONCHODILATORS MARKET BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 25. MEXICO BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 26. MEXICO BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 27. MEXICO BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 28. EUROPE BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 29. EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 30. EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 31. EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 32. GERMANY BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 33. GERMANY BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 34. GERMANY BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 35. FRANCE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 36. FRANCE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 37. FRANCE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 38. U.K. BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 39. U.K. BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 40. U.K. BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 41. REST OF EUROPE BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 42. REST OF EUROPE BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 43. REST OF EUROPE BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 45. ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 46. ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 48. JAPAN BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 49. JAPAN BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 50. JAPAN BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 51. CHINA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. CHINA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 53. CHINA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 54. INDIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 55. INDIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 56. INDIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 60. LAMEA BRONCHODILATORS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 61. LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 62. LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION),
TABLE 63. LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 64. BRAZIL BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. BRAZIL BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 66. BRAZIL BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 67. SAUDI ARABIA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 68. SAUDI ARABIA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 69. SAUDI ARABIA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 70. SOUTH AFRICA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 71. SOUTH AFRICA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 72. SOUTH AFRICA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 73. REST OF LAMEA BRONCHODILATORS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 74. REST OF LAMEA BRONCHODILATORS MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 75. REST OF LAMEA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 76. ABBOTT: COMPANY SNAPSHOT
TABLE 77. ABBOTT: OPERATING BUSINESS SEGMENTS
TABLE 78. ABBOTT PRODUCT PORTFOLIO
TABLE 79. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 80. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 81. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 82. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 83. BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 84. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 85. GSK.: COMPANY SNAPSHOT
TABLE 86. GSK.: OPERATING BUSINESS SEGMENTS
TABLE 87. GSK.: PRODUCT PORTFOLIO
TABLE 88. ROCHE: COMPANY SNAPSHOT
TABLE 89. ROCHE: OPERATING SEGMENTS
TABLE 90. NOVARTIS: COMPANY SNAPSHOT
TABLE 91. NOVARTIS: OPERATING BUSINESS SEGMENTS
TABLE 92. NOVARTIS: PRODUCT PORTFOLIO
TABLE 93. PFIZER: COMPANY SNAPSHOT
TABLE 94. PFIZER: OPERATING SEGMENTS
TABLE 95. PFIZER: PRODUCT PORTFOLIO
TABLE 96. SANOFI: COMPANY SNAPSHOT
TABLE 97. SANOFI: OPERATING SEGMENTS
TABLE 98. SANOFI: PRODUCT PORTFOLIO
TABLE 99. TEVA: COMPANY SNAPSHOT
TABLE 100. TEVA: PRODUCT PORTFOLIO
TABLE 101. VECTURA: COMPANY SNAPSHOT
TABLE 102. VECTURA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. BRONCHODILATORS, MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING
FIGURE 04. DRIVERS, RESTRAINT, AND OPPORTUNITY, BRONCHODILATORS MARKET
FIGURE 05. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ASTHMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 06. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 07. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF SYMPATHOMIMETICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR ANTICHOLINERGICS BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR PHOSPHODIESTERASE INHIBITORS BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR COMBINATION DRUGS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INJECTION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS MARKET, FOR INHALER BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 16. ABBOTT: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 17. ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 22. BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. GSK: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. ROCHE: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 28. ROCHE: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 29. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 32. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 34. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. SANOFI: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 37. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. VECTURA: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. VECTURA: REVENUE SHARE BY REGION, 2018 (%)

 
 

Bronchodilators are used to lighten or loosen the mucus formed in lungs of patients suffering from respiratory disorders such as asthma and COPD. These devices enable patients to breathe properly and relieve chest pain by lung expansion and clearing excessive mucus formation. Further, increased usage of bronchodilators for treatment of chronic respiratory disorders is expected to boost the market growth. In addition, availability of various types of bronchodilators, such as short acting and long acting, is anticipated to boost the market growth in the \ future.

The bronchodilators market is anticipated to witness a steady growth in the future, owing to its increased use in patients suffering from bronchiectasis. However, high cost of these systems and stringent reimbursement scenario is expected to hamper the market growth in the future. Moreover, North America dominated the market in 2018, owing to surge in prevalence of respiratory disorders and awareness among patients toward the availability of these drugs. Asia-Pacific is anticipated to grow at the fastest growth rate in the future, owing to significant surge in the prevalence of COPD and asthma.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Bronchodilators Market is $27,580.3 million in 2018.

A. The forecast period for Bronchodilators Market is 2019 to 2026

A. The market value of Bronchodilators Market in 2019 is $29,118.6 million

A. The base year is 2018 in Bronchodilators Market

A. Top companies such as, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., held a high market position in 2018.

A. Anticholinergics segment is the most influencing segment growing in the Bronchodilators Market

A. The key trend in the Bronchodilators Market is increase in incidence of asthma and COPD across the globe which drives the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China and India with a CAGR of 7.3% and 8.4% respectively.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Bronchodilators Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts